文献速递临床试验与 GCP基础与转化研究

尼达尼布治疗肺移植后进行性闭塞性细支气管炎综合征(BOS)0p-1-2级:INFINITIx-BOS法国多中心随机对照试验方案

Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial.
PubMed 文献 · Trials · 2026-04-11

INFINITIx-BOS是一项研究者发起的法国多中心II期优效性双盲随机对照试验,计划纳入80例肺移植后至少6个月、过去一年内进行性BOS的受者,随机接受尼达尼布150 mg每日两次或安慰剂治疗6个月,主要终点为6个月治疗期间下降斜率。

要点

  • 肺移植后BOS是CLAD最常见表型,目前无获批治疗。
  • 尼达尼布基于IPF抗纤维化疗效及BOS纤维化通路被选为候选药物。
  • 试验纳入进行性BOS 0p-1-2级受者,评估6个月下降斜率。

核心结论

  • 基于IPF与BOS部分共享纤维化模式,INFINITIx-BOS试验有望证明尼达尼布作为靶向纤维化通路的附加策略。

研究设计与样本

  • 研究者发起的法国全国多中心II期优效性平行组双盲比较随机对照试验。
  • 计划纳入80例肺移植后至少6个月、过去一年内进行性BOS的受者。
  • 随机接受尼达尼布150 mg每日两次或安慰剂治疗6个月,并维持免疫抑制治疗。

关键数值与推荐

  • 主要终点为6个月治疗期间下降斜率。
  • 次要终点包括6分钟步行试验、SGRQ、移植物衰竭、SPO2及6个月内安全性事件的变化。

临床怎么用

  • 若证实有效,尼达尼布可能成为肺移植后进行性BOS的靶向抗纤维化附加治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term survival after lung transplantation (LTx) is still hampered by the development of chronic allograft dysfunction (CLAD). Bronchiolitis obliterative syndrome (BOS), the most common phenotype of CLAD, is thought to arise from repeated injuries to graft epithelial cells, leading to fibrous scarring of small airways. Thus far, there is no approved treatment for BOS disease. Based on both animal/human studies in LTx and the demonstrated efficacy of the TKI nintedanib treatment in idiopathic pulmonary fibrosis (IPF), nintedanib is a candidate molecule capable of stopping the fibroproliferative process in BOS. Hence, the rationale to conduct a nintedanib trial in LTx recipients with BOS is based on (i) an unmet medical need due to poor survival after BOS diagnosis; (ii) the demonstrated fibrotic pathways in BOS; and (iii) the proven efficacy of nintedanib in IPF. METHODS: The INFINITIx-BOS study is an investigator-initiated, national multicentric, phase II, superiority, parallel-group, double-blind, comparative randomized clinical trial. A total of 80 recipients with progressive BOS within the prior year, at least at 6 months post-LTx, will be randomized to receive either nintedanib (150 mg bid) or placebo for a period of 6 months, in addition to maintenance immunosuppressive therapy left to their physician's discretion with 4 dedicated visits. The primary endpoint is the slope of decline over 6 months of treatment. The secondary endpoints are change in 6-min walk test, SGRQ, graft failure, SPO2, and safety events over 6 months, which will be compared between the two arms. DISCUSSION: Based on a fibrotic pattern partially shared between IPF and BOS, this randomized INFINITIx-BOS trial has the potential to demonstrate an additional strategy with nintedanib as a targeted-fibrotic pathway associated with BOS. TRIAL REGISTRATION NUMBER: NCT03283007, first posted 11 September 2017. Protocol version identifier No. 6-0, 8 September 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Brugière O, Hirschi S, Reynaud-Gaubert M, et al. Nintedanib in progressive bronchiolitis obliterans syndrome (BOS) grade 0p-1-2 in lung transplant recipients (INFINITIx-BOS): protocol of a French multicenter randomized controlled trial. Trials. 2026. PMID: 41964069. doi:10.1186/s13063-025-09314-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。